Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Php Biotech International Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action serves as the primary focus for the company patent portfolio at the patent office. The current prosecution activity is concentrated within this specific technical sector.
The portfolio involves 1 distinct examiner and 1 distinct art unit. Such a focused prosecution footprint suggests that the legal strategy is tailored to a specific set of regulatory requirements. Operating within 1 distinct art unit simplifies the administrative tracking of the active matter.
MOEHLMAN, ANDREW TERRY is the busiest examiner for this portfolio, currently overseeing 1 pending office action. Because this examiner is the only official listed, the outcome of the current filing depends entirely on this individual's assessment. Maintaining clear communication with the assigned examiner is essential for advancing the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOEHLMAN, ANDREW TERRY | 1 | 66.3% | +61.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18313141 | Bioactive Peptides, Compositions, Production Process, and Use of Bioactive Peptides as Anti-Tumoral Agents | MOEHLMAN, ANDREW TERRY | 18d overdue |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18313141 | Bioactive Peptides, Compositions, Production Process, and Use of Bioactive Peptides as Anti-Tumoral Agents | MOEHLMAN, ANDREW TERRY | 1655 | §112 | Final Rejection | 18d overdue | Pending | May 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial